Increased mortality associated with meticillin-resistant Staphylococcus aureus (MRSA) infection in the Intensive Care Unit: results from the EPIC II study
Introduction
Staphylococcus aureus is a common cause of infection in intensive care patients and in many cases it is resistant to meticillin [1]. However, whether meticillin resistance increases mortality in patients with S. aureus infection remains controversial. Some investigations and meta-analyses have reported that meticillin resistance does increase the mortality risk [2], [3], [4], [5], [6], [7], whereas others have been unable to demonstrate any difference in mortality between meticillin-resistant S. aureus (MRSA) and meticillin-sensitive S. aureus (MSSA) infections [8], [9], [10], [11], [12], [13], [14], [15]. The conflicting results may be explained by differences in setting, sample size, case mix, strain virulence, minimum inhibitory concentration (MIC), antibiotic choice, antibiotic dosage and timing of appropriate antimicrobial therapy.
The 1-day point-prevalence Extended Prevalence of Infection in the ICU (EPIC II) study showed that, on the day of the study, 7087 (51%) of 13 796 patients were classified as infected, and 70% of these had positive cultures; 47% of the positive isolates were Gram-positive [16]. The five most commonly isolated organisms were S. aureus (20.5%), Pseudomonas spp. (19.9%), Candida spp. (17.0%), Escherichia coli (16%) and Klebsiella spp. (12.7%); 49.4% of the S. aureus isolates were MRSA [16].
The purpose of the present study was to compare the characteristics of patients with MRSA and MSSA infections in the EPIC II study cohort and to assess the independent role of meticillin resistance in mortality in these patients.
Section snippets
Methods
The EPIC II 1-day point-prevalence study of infection in critically ill patients was performed on 8 May 2007 [16]. Demographic, physiological, bacteriological and therapeutic data were collected from 13 796 adult (>18 years) patients in 1265 participating Intensive Care Units (ICUs) (Supplementary Appendix A) from 75 countries on the study day, as described previously [16]. Simplified Acute Physiology Score (SAPS) II and Sequential Organ Failure Assessment (SOFA) scores were calculated for the
Characteristics of patients with MRSA versus MSSA infections
There was considerable variation in the percentages of patients with MRSA/MSSA according to geographical region (Fig. 1). The characteristics of patients with MRSA (n = 494) and MSSA (n = 505) infections are shown in Table 1. There were no differences in SAPS II and SOFA scores on admission between groups. Patients with MRSA were slightly older and had longer ICU stays prior to the study date than those with MSSA [median (IQR) 10 days (3–22 days) vs. 7 days (3–14 days); P < 0.001]. Patients with MSSA
Discussion
The main findings of this study are that, in ICU patients, MRSA infections are more frequent in patients with underlying co-morbid conditions, such as cancer and chronic renal failure, and are associated with a 50% greater likelihood of hospital death compared with MSSA infections. Patients with MRSA infection are also more likely to have concomitant infection with Pseudomonas spp., Enterococcus, Acinetobacter spp. or Candida spp. These findings are in agreement with several other studies [6],
Acknowledgment
The authors thank Hassane Njimi, MSc, PhD (Department of Intensive Care, Erasme University Hospital, Brussels, Belgium) for help with data management and statistical analyses.
Funding: No funding sources.
Competing interests: JR participated as a consultant and as a member of the speaker's bureau for Pfizer. All other authors declare no competing interests.
Ethical approval: Ethics committee approval was obtained from individual centers.
References (30)
- et al.
Clinical impact of methicillin resistance on outcome of patients with Staphylococcus aureus infection: a stratified analysis according to underlying diseases and sites of infection in a large prospective cohort
J Infect
(2010) - et al.
Are infections due to resistant pathogens associated with a worse outcome in critically ill patients?
J Infect
(2003) - et al.
Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia
Chest
(2005) - et al.
Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005–2006)
Diagn Microbiol Infect Dis
(2008) - et al.
Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia
Chest
(2010) - et al.
Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method
BMC Infect Dis
(2010) - et al.
Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia
J Infect Chemother
(2011) - et al.
Impact of inappropriate empirical therapy for sepsis due to health care-associated methicillin-resistant Staphylococcus aureus
J Infect
(2009) - et al.
Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock
Chest
(2009) - et al.
Case–control study to identify factors associated with mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia
Clin Microbiol Infect
(2010)